Pfizer
Pfizer begins using ‘digital’ reps
September 24, 2013Medical Communications, Sales and Marketing Pfizer, online, pfizerline, reps
Pfizer has begun using digital drug representatives to market medicines, leaving the decision as to whether they want to see …
Pfizer launches trial data sharing service
September 23, 2013Medical Communications, Sales and Marketing Pfizer, blue button
Pfizer has launched a first-of-its-kind project that enables patients who have participated in clinical trials the ability to download their …
Regeneron appoints senior VP from Pfizer
September 11, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pfizer, Regeneron, landry
Regeneron Pharmaceuticals has hired Robert Landry from Pfizer to be its senior vice president and chief financial officer. Landry will …
EFPIA slams EMA data proposals
September 10, 2013Research and Development, Sales and Marketing AZ, EFPIA, EMA, GSK, Pfizer, Roche
The intense debate over how pharma should make trial data available has taken another turn as a major European industry …
NICE queries pharma R&D costs
September 5, 2013Research and Development, Sales and Marketing Dillon, NICE, Pfizer, R&D
NICE has questioned whether pharma really spends as much as it says it does on bringing new treatments to market …
Pfizer joins Amazon-like R&D network
August 30, 2013Medical Communications Assay Depot, Pfizer, amazon
Pfizer has become the latest big pharma firm to sign up to Assay Depot, the Amazon-like virtual laboratory. The US …
Price cut not enough for Pfizer’s Xalkori
August 16, 2013Sales and Marketing NICE, Pfizer, Xalkori, lung cancer
In final draft guidance NICE has rejected Pfizer’s new lung cancer drug Xalkori because of its high cost. The Institute …
Lipitor competition holds Pfizer back
July 31, 2013Sales and Marketing Lipitor, Pfizer, Prevnar, Q2
Pfizer’s revenues in the second quarter of 2013 fell 7% year-on-year, in part due to the loss of patent in …
January deadline for Pfizer restructure
July 30, 2013Research and Development, Sales and Marketing Pfizer, patent, restructure
Pfizer is to restructure operations from January 2014 in a bid to make its business more responsive to patient and …
NICE rejects Pfizer blood cancer drug
July 16, 2013Sales and Marketing BMS, CML, NICE, Pfizer, bosulif
NICE is not recommending Pfizer’s blood cancer drug Bosulif due to uncertainties over its cost effectiveness and survival benefit. In …
Irish eyes smiling as Pfizer plans $130m investment
July 15, 2013Manufacturing and Production IDA, Pfizer, cork, grange
The company has said it will spend $100m upgrading its Grange Castle site in Dublin and $30m at Ringaskiddy in …
Novartis compound beats Enbrel
July 9, 2013Sales and Marketing Enbrel, Novartis, Pfizer, skin
One of Novartis’ investigational drugs has beaten Pfizer’s Enbrel in a head-to-head Phase III psoriasis study and is on course …
VTE boost for Eliquis
July 2, 2013Research and Development, Sales and Marketing AMPLIFY, BMS, DVT, Eliquis, Pfizer
Bristol-Myers Squibb and Pfizer’s oral blood thinner Eliquis is as efficient as standard of care and causes less bleeding in …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
